Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Nemolizumab is Associated with a Rapid Improvement in Atopic Dermatitis Signs and Symptoms: Subpopulation (EASI ≥16) Analysis of Randomized Phase 2B Study.

< BACK TO ARCHIVE


2021 Mar 12


J Eur Acad Dermatol Venereol


http://www.ncbi.nlm.nih.gov/pubmed/33711179?dopt=Abstract

Nemolizumab is Associated with a Rapid Improvement in Atopic Dermatitis Signs and Symptoms: Subpopulation (EASI ≥16) Analysis of Randomized Phase 2B Study.

Authors

Nemolizumab is Associated with a Rapid Improvement in Atopic Dermatitis Signs and Symptoms: Subpopulation (EASI ≥16) Analysis of Randomized Phase 2B Study.
Silverberg JI, Pinter A, Alavi A, Lynde C, Bouaziz J-D, Wollenberg A, Murrell DF, Alpizar S, Laquer V, Chaouche K, Ahmad F, Armstrong JM, Piketty C
J Eur Acad Dermatol Venereol. 2021 Mar 12.
PMID: 33711179.

Abstract

Nemolizumab is a humanized anti-IL-31 receptor blocker in phase 3 for atopic dermatitis (AD).
Read This Paper